The Cardima Systemwas presented as technology that has the ability to create transmural,continuous linear lesions, using the least Invasive approach for epicardialablation via the thoracoscopic approach. This is critical to be able totreat lone AF, decrease patient procedure time and post-operative recoverytime.
Dr. Adam Saltman: Surgical Study Published
Dr. Adam Saltman's paper, "Histopathological Evaluation of a NovelRadiofrequency Surgical Ablation System," an evaluation of the CardimaSurgical Ablation System, has been published in Innovations Volume 3,Number 2, March 2008, the Journal of the International Society of MinimallyInvasive Cardiothoracic Surgery. This paper concludes the Cardima SurgicalAblation System produces histolgically transmural lesions and is applicableto beating heart thorocoscopic surgery. This paper is an importantcorroboration of the ability of the Cardima Surgical Ablation System tocreate long transmural lesions using minimally invasive surgical techniquesin a safe and effective manner. Dr. Saltman commented as follows, "My workwith the Cardima Surgical Ablation System indicates that the System can beused as an effective tool for the surgical ablation of atrial fibrillationusing a minimally invasive thorocoscopic approach."
Dr. Saltman is a trained cardiothoracic surgeon who currently practices atMaimonides Medical Center in New York.
Dr. Mark La Meir: University of Maastricht
Dr. Mark La Meir, a well-known cardiothoracic surgeon who teaches at theUniversity of Maastricht, located in the Netherlands, has conducted anaggressive animal study using the Cardima Surgical Ablation System. Basedon his findings, he concurs the Cardima Surgical Ablation System is able toproduce highly transmural lesions. Cardima and Dr. La Meir intend tocontinue working together on further studies with the intention ofpresenting scientific medical data to the European medical community. Dr.La Meir commented on his recent work with Cardima, "I was very impressed bythe Cardima Surgical Ablation System and its ability to make long,transmural lesions. We are looking forward to working closely with Cardimato conduct further research as well as treating lone AF patients at ourcenter."
About Cardima
Cardima, Inc. has developed the PATHFINDER®, TRACER® and VUEPORT®Series of diagnostic catheters, the NAVIPORT® Series of guidingcatheters, the REVELATION® Series of ablation catheters, the SurgicalAblation System with its series of ablation probes, and the INTELLITEMP®Energy Management Device Series for RF (radiofrequency) energy management.These devices are CE marked and/or received U.S. FDA 510(k) clearance.
